Pharmabiz
 

Akums Drugs: setting new standards in Indian healthcare

Thursday, November 22, 2012, 08:00 Hrs  [IST]

Akums, which was established in the year 2004 as contract manufacturing company with just one plant for manufacturing solid oral dosage forms, in a span of eight years , has become an icon, setting new standards in the Indian healthcare industry.

In a way it started a new chapter of Contract Research & Manufacturing Service (CRAMS) in the Indian pharmaceutical industry. Due to their faith in its quality, most of the leading marketing companies of the country switched over to contract manufacturing of their prestigious formulations to Akums . Today, Akums is not merely known as a  contract manufacturing company but has earned  reputation as a technology driven & research - oriented organization with lot of innovative formulations and dosage forms in its product range.

Due to popular demand from its clients for other dosage forms, Akums set up five more manufacturing  units for producing formulations in practically all dosage forms, including dry/liquid injections, large volume parenterals, pre-filled syringes, liquid orals, eye/ear drops and therapeutic segments including hormonal. Akums manufacturing facilities are rated as the best in the country with a number of national and international accreditations.

Akums new products’ development department has more than 300 new FDCs and molecules to its credit, which have been developed by them and approved by DCGI for manufacturing and marketing in the country. More than 60 innovative products developed by its formulation & development department have been filed for patenting.

Akums has also developed products in unique dosage form such as tablet-in-tablet, multiple tablets in capsule, antibiotic syrups in ready to use form, medicinal jelly, medicinal chewing gums, mouth dissolving tablets/ powder etc.

Akums has developed specialized products such as : Paracetamol 100 ml Infusion, Ofloxacin + Ornidazole 100 ml Infusion, Diclofenac 75 mg/ml, Diclofenac 50 mg powder in sachet, Cefexime + Ornidazole tabs, Cefpodoxime + Clavulanic tabs, Cefpodoxime + Ofloxacin tabs,

Cefexime mouth dissolving tabs, Lornoxicam mouth dissolving tabs, Amoxycillin + Clavulanic Solutab, Cefurexime – Gastric floating immediate & sustained release tabs, ready to use Cephalosporin suspension with lactic acid bacillus, ready to use Azithromycin taste masked suspension, Azithromycin powder in scahet, Progesterone effervescent vaginal/oral tablets, Progesterone Gel, Caffeine Citrate injection, Zoledronic Acid 100 ml infusion, Atorvastatin + Vitamin D3, Metformin + Voglibose + Glimepride , Trypsin + Bromelaine + Rutaside + Harpagpphtum and many others.

Akums full-fledged regulatory department with qualified and experienced personnel prepares dossiers as per CTD, ACTD & guidelines of MOH of different countries and has already submitted 300 dossiers in different countries.

Akums facilities have been audited & approved by several international regulatory bodies, namely; ANVISA-Brazil, NAFDAC-Nigeria, PPB-Kenya, NDA-Uganda, PMPB-Malawi, FDB-Ghana, MoH-Libya, MoH-Vietnam, DPM- Ivory Coast, CD&DA- Sri Lanka as well as regulatory authorities of a number Indian & multi-national companies for whom Akums is undertaking contract manufacturing.

To meet the emerging demand of herbal medicines across the globe, Akums has set up a separate state-of-the-art-manufacturing facility to produce high quality herbal, nutraceutical & food supplement products at its 100 per cent owned subsidiary Plant – VI, Maxcure Nutravedics Ltd, which is US-NSF certified and produces formulations in the form of tablets, capsules (hard/soft gel.), liquid orals and powder.

Maxcure has developed unique products for most prevailing diseases, such as male pattern baldness ( alopecia), hypertension, anxiety, diabetes, supplement for gout management (uric acid) , aphrodisiac, supplement for weight management (obesity), mouth dissolving antacid powder, cough syrup for varied etiology in different dosage forms have been developed and are being marketed by its client in India.

 
[Close]